Related Experiment Video
Updated: Jul 5, 2025
Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
Published on: April 12, 2021
Benefits of statin therapy within a year after kidney transplantation
Seung Hyuk Yim1, Hyun Jeong Kim1, Han Ro2
1Department of Surgery, The Research Institute for Transplantation, Yonsei University College of Medicine, Seoul, South Korea.
Insights
Early statin use after kidney transplantation (KT) significantly lowers mortality and death-censored graft loss. This strategy effectively reduces low-density lipoprotein cholesterol, improving patient and graft survival post-transplantation.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Cardiovascular disease is a major cause of death and illness in kidney transplant recipients.
- Statins are known to reduce cardiovascular risk and benefit kidney function in the general population, but their impact on kidney transplant patients is unclear.
Purpose of the Study:
- To investigate the long-term effects of early statin use on outcomes in kidney transplant recipients.
Main Methods:
- A cohort study of 714 kidney transplant recipients in Korea.
- Analysis of outcomes including mortality, death-censored graft loss, and major adverse cardiovascular events in patients receiving statins within one year post-transplantation compared to a control group.
Main Results:
- Early statin use was linked to significantly lower mortality (HR 0.280) and death-censored graft loss (HR 0.350).
- Statin therapy effectively reduced low-density lipoprotein cholesterol levels.
- No significant difference was observed in major adverse cardiovascular events, biopsy-proven rejection, or graft renal function between groups.
Conclusions:
- Early statin administration is a beneficial strategy for improving patient and graft survival after kidney transplantation.
- Statin therapy is effective in lowering LDL cholesterol in kidney transplant recipients.
Abstract:
Cardiovascular disease remains a leading cause of morbidity and mortality after kidney transplantation (KT). Although statins reduce cardiovascular risk and have renal benefits in the general population, their effects on KT recipients are not well-established. We studied the effects of early statin use (within 1-year post-transplantation) on long-term outcomes in 714 KT recipients from the Korean cohort study for outcome in patients with KT. Compared with the control group, statin group recipients were significantly older, had a higher body mass index, and had a higher prevalence of diabetes mellitus. During a median follow-up of 85 months, 74 graft losses occurred (54 death-censored graft losses and 20 deaths). Early statin use was independently associated with lower mortality (hazard ratio, 0.280; 95% confidence interval 0.111-0.703) and lower death-censored graft loss (hazard ratio, 0.350; 95% confidence interval 0.198-0.616). Statin therapy significantly reduced low-density lipoprotein cholesterol levels but did not decrease the risk of major adverse cardiovascular events. Biopsy-proven rejection and graft renal function were not significantly different between statin and control groups. Our findings suggest that early statin use is an effective strategy for reducing low-density lipoprotein cholesterol and improving patient and graft survival after KT.
